Company: Eli Lilly
2016 U.S. sales: $535 million
U.S. patent expiration date: May 26
Lilly’s Strattera may have chipped in U.S. sales above $500 million for 2016, but it's headed for a quick descent. When it’s all done, the drug’s U.S. sales in 2022 are expected to be lower than any other on the list of Top 10 U.S. Patent losses for 2017.
Strattera will lose its patent protection May 26, according to EvaluatePharma and Drug Patent Watch. Lilly itself has guided for May 2017 but didn’t specify a date.
Used to treat ADHD, Strattera is one of several drugs that Lilly said it’d stop promoting when the company chopped its sales force in the wake of an Alzheimer’s disease trial failure in December. The drug first won FDA approval in 2002.
So far, generics makers Apotex, Aurobindo, Sandoz, Glenmark, Sun Pharma, Mylan and Dr. Reddy’s have tentative approvals for copycats, according to Drugs@FDA.
After turning in U.S. sales of $535 million for 2016, the drug is set to lose more than $300 million this year. Analysts at EvaluatePharma are predicting $211 million this year, $64 million for 2018 and then a downward trajectory to $13 million by 2022.
Around the world, Lilly reported $855 million in Strattera sales for 2016.